Your browser doesn't support javascript.
loading
Interferon-Driven Immune Dysregulation in Common Variable Immunodeficiency-Associated Villous Atrophy and Norovirus Infection.
Strohmeier, Valentina; Andrieux, Geoffroy; Unger, Susanne; Pascual-Reguant, Anna; Klocperk, Adam; Seidl, Maximilian; Marques, Otavio Cabral; Eckert, Marleen; Gräwe, Katja; Shabani, Michelle; von Spee-Mayer, Caroline; Friedmann, David; Harder, Ina; Gutenberger, Sylvia; Keller, Baerbel; Proietti, Michele; Bulashevska, Alla; Grimbacher, Bodo; Provaznik, Jan; Benes, Vladimir; Goldacker, Sigune; Schell, Christoph; Hauser, Anja E; Boerries, Melanie; Hasselblatt, Peter; Warnatz, Klaus.
Afiliación
  • Strohmeier V; Department of Rheumatology and Clinical Immunology, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
  • Andrieux G; Center for Chronic Immunodeficiency (CCI), Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
  • Unger S; Faculty of Biology, University of Freiburg, Freiburg, Germany.
  • Pascual-Reguant A; Institute of Medical Bioinformatics and Systems Medicine, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
  • Klocperk A; Department of Rheumatology and Clinical Immunology, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
  • Seidl M; Center for Chronic Immunodeficiency (CCI), Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
  • Marques OC; Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität Zu Berlin, Charitéplatz 1, 10117, Berlin, Germany.
  • Eckert M; Immune Dynamics, Deutsches Rheuma-Forschungszentrum (DRFZ), a Leibniz Institute, Charitéplatz 1, 10117, Berlin, Germany.
  • Gräwe K; Department of Rheumatology and Clinical Immunology, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
  • Shabani M; Center for Chronic Immunodeficiency (CCI), Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
  • von Spee-Mayer C; Department of Immunology, 2Nd Faculty of Medicine, Charles University and University Hospital in Motol, Prague, Czech Republic.
  • Friedmann D; Institute for Surgical Pathology, University Medical Center Freiburg, Freiburg, Germany.
  • Harder I; Institute of Pathology, Heinrich Heine University and University Hospital of Dusseldorf, Dusseldorf, Germany.
  • Gutenberger S; Department of Rheumatology and Clinical Immunology, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
  • Keller B; Center for Chronic Immunodeficiency (CCI), Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
  • Proietti M; Department of Immunology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, SP, Brazil.
  • Bulashevska A; Department of Clinical and Toxicological Analyses, School of Pharmaceutical Sciences, University of São Paulo, São Paulo, SP, Brazil.
  • Grimbacher B; Network of Immunity in Infection, Malignancy, and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), São Paulo, SP, Brazil.
  • Provaznik J; Department of Pharmacy and Postgraduate Program of Health and Science, Federal University of Rio Grande do Norte, Natal, Brazil.
  • Benes V; Department of Rheumatology and Clinical Immunology, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
  • Goldacker S; Center for Chronic Immunodeficiency (CCI), Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
  • Schell C; Faculty of Biology, University of Freiburg, Freiburg, Germany.
  • Hauser AE; Institute for Surgical Pathology, University Medical Center Freiburg, Freiburg, Germany.
  • Boerries M; Institute for Surgical Pathology, University Medical Center Freiburg, Freiburg, Germany.
  • Hasselblatt P; Department of Rheumatology and Clinical Immunology, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
  • Warnatz K; Center for Chronic Immunodeficiency (CCI), Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
J Clin Immunol ; 43(2): 371-390, 2023 02.
Article en En | MEDLINE | ID: mdl-36282455
PURPOSE: About 15% of patients with common variable immunodeficiency (CVID) develop a small intestinal enteropathy, which resembles celiac disease with regard to histopathology but evolves from a distinct, poorly defined pathogenesis that has been linked in some cases to chronic norovirus (NV) infection. Interferon-driven inflammation is a prominent feature of CVID enteropathy, but it remains unknown how NV infection may contribute. METHODS: Duodenal biopsies of CVID patients, stratified according to the presence of villous atrophy (VA), IgA plasma cells (PCs), and chronic NV infection, were investigated by flow cytometry, multi-epitope-ligand cartography, bulk RNA-sequencing, and RT-qPCR of genes of interest. RESULTS: VA development was connected to the lack of intestinal (IgA+) PC, a T helper 1/T helper 17 cell imbalance, and increased recruitment of granzyme+CD8+ T cells and pro-inflammatory macrophages to the affected site. A mixed interferon type I/III and II signature occurred already in the absence of histopathological changes and increased with the severity of the disease and in the absence of (IgA+) PCs. Chronic NV infection exacerbated this signature when compared to stage-matched NV-negative samples. CONCLUSIONS: Our study suggests that increased IFN signaling and T-cell cytotoxicity are present already in mild and are aggravated in severe stages (VA) of CVID enteropathy. NV infection preempts local high IFN-driven inflammation, usually only seen in VA, at milder disease stages. Thus, revealing the impact of different drivers of the pathological mixed IFN type I/III and II signature may allow for more targeted treatment strategies in CVID enteropathy and supports the goal of viral elimination.
Asunto(s)
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Inmunodeficiencia Variable Común / Infecciones por Caliciviridae / Norovirus Tipo de estudio: Risk_factors_studies Límite: Humans Idioma: En Revista: J Clin Immunol Año: 2023 Tipo del documento: Article País de afiliación: Alemania

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Inmunodeficiencia Variable Común / Infecciones por Caliciviridae / Norovirus Tipo de estudio: Risk_factors_studies Límite: Humans Idioma: En Revista: J Clin Immunol Año: 2023 Tipo del documento: Article País de afiliación: Alemania